TOBY Wins FDA Breakthrough Status for AI Bladder Cancer Urine Test, Targets Launch in 1 Year
Updated
Updated · The Washington Post · Nov 1
TOBY Wins FDA Breakthrough Status for AI Bladder Cancer Urine Test, Targets Launch in 1 Year
1 articles · Updated · The Washington Post · Nov 1
Summary
FDA granted Breakthrough Device designation to TOBY’s AI-based urine test for bladder cancer, a step that can speed review and puts the product about a year from commercial launch, according to its developers.
Rather than relying on a single biomarker, the test analyzes patterns of volatile organic compounds wafting from urine, using improved molecular detection tools and machine learning to turn body-odor signals into a noninvasive diagnostic.
The designation adds to growing momentum for odor-based medicine, where researchers are pursuing breath, urine and sebum tests for cancers, Alzheimer’s, Parkinson’s and infections, though standardization and larger-study validation remain major hurdles.
TOBY already received FDA Breakthrough status in May for a similar Alzheimer’s test, underscoring broader efforts to bring VOC-based diagnostics from research labs into clinics.